Neglected Tropical Disease

$100 million*

Minimum Requirement for American Leadership

 
The USAID Neglected Tropical Disease (NTD) program was established in 2006 and has made important and substantial contributions to the global fight to control and eliminate seven of the most common NTDs.

Download PDF

Justification for Funding

  • Many of the most common NTDs are combated using medicines that are safe and effective. USAID funding enables medicines to reach people at-risk, which contributes to NTD prevention, control, and elimination. However, treatment options for NTDs with the highest death rates, including human African trypanosomiasis, visceral leishmaniasis, and Chagas disease, are extremely limited.
  • Since its start in 2006, USAID has supported the distribution of 1.42 billion safe and effective NTD treatments to more than 935 million people in Africa, Asia, and Latin America.
  • Investments are urgently needed to support R&D for new tools, including diagnostics, drugs, and vaccines, for all NTDs. Addressing the link between health and other sectors, along with increased R&D, are necessary to meet the World Health Organization’s (WHO) NTD 2020 goals.

Cost of Cuts Below $100 Million

President and Congress Budget Comparison

       Congressional Budget   

       President's Budget Request (Base + OCO)

  • NTDs are responsible for as many as 534,000 deaths every year. Additionally, over 800 million children are impacted by NTDs leading to blindness, deformities, and malnutrition.
  • A decrease in funding would have implications for these statistics worsening due to less aid and resources available to treat or prevent NTDs among vulnerable populations. There could also be a decrease in the gains made to reduce and eliminate NTDs in the countries where the program has been implemented over the past ten years.

$125 million

Opportunity to Catalyze American Leadership

 

Justification for Additional Funding

  • The USAID NTD program provides direct funding support, technical assistance, and training to 31 national NTD programs, while informing the global policy dialogue on NTDs.
  • Since 2014, the program has been investing in research and development to ensure that promising new breakthrough medicines for parasitic filarial diseases can be rapidly evaluated, registered, and made available to patients.
  • Without an increase in funding, the goals of the NTD program to eliminate seven of the most common NTDs by 2020 would not be met; level funding will not allow the program goals to advance.

Impact of 25% More Funding

As a result of USG funding for NTDs and other global support: 198 million people are no longer at risk for lymphatic filariasis or elephantiasis and 85 million people are no longer at risk for blinding trachoma.

  • With 25% increase in funding for FY2019, the program can maximize the benefits of increased drug donations received from pharmaceutical companies; to ensure that all countries supported by USAID’s program can reach national scale and maintain the great progress towards 2020 control and elimination targets; and to continue urgently needed investments in research and development for new tools – including diagnostics, drugs, and vaccines – for all NTDs to ensure that new discoveries make it through the pipeline and become available to people who need them most.

*Enacted FY18 Omnibus Appropriation

For more information, please contact: Soshana Hashmie, shashmie@interaction.org

Choose to Invest:   2018  |  2017  |  2016  |  2015  |  2014  |  2013  |  2012